SeaCrest Wealth Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

SeaCrest Wealth Management’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-15,834	Closed	-$297K	–	563
2019 Q3	$297K	Sell	15,834 -3,529	-18%	-$71.7K	0.06%	397
2019 Q2	$409K	Buy	19,363 +18,213	+1,584%	+$375K	0.08%	291
2019 Q1	$24K	Sell	1,150 -250	-18%	-$5.25K	﹤0.01%	1210
2018 Q4	$26K	Hold	1,400	–	–	0.01%	1129
2018 Q3	$35K	Hold	1,400	–	–	0.01%	1144
2018 Q2	$34K	Hold	1,400	–	–	0.01%	1136
2018 Q1	$41K	Hold	1,400	–	–	0.01%	1034
2017 Q4	$33K	Buy	+1,400	New	+$35.4K	0.01%	1131

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

SeaCrest Wealth Management's CNCR Position: Q4 2019 in Review

SeaCrest Wealth Management sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2019, closing a stake of 15,834 shares — an estimated $297K sold.

SeaCrest Wealth Management first reported a position in CNCR in Q4 2017 and held it in 8 quarters. The position peaked at $409K in Q2 2019. 23 funds tracked by Wall St. Rank hold CNCR as of Q4 2019.

SeaCrest Wealth Management reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 15,834 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2019, an estimated $297K.
SeaCrest Wealth Management first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2017 and held it in 8 quarters.
SeaCrest Wealth Management's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $409K in Q2 2019.
23 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2019.

Based on SeaCrest Wealth Management's 13F filing for Q4 2019, filed 22 Jan 2020.